Evidence also demonstrated that NAA10 is highly upregulated in various malignancies, including breast, bone, colorectal, liver, lung, and prostate cancers, and that expression level of NAA10 is correlated with the cancer progression, an implication for possibility of NAA10 as a cancer biomarker [4,5,6,7,8,9]. Here, NAA10 is linked to prostate carcinoma.